Adaptive Biotechnologies to Participate in Upcoming Investor Conferences
Rhea-AI Summary
Adaptive Biotechnologies (Nasdaq: ADPT) will participate in two investor conferences in late 2025: a presentation at the Jefferies Global Healthcare Conference in London on November 19, 2025 at 8:00 a.m. GMT, and a fireside chat at the Piper Sandler 37th Annual Healthcare Conference in New York on December 3, 2025 at 8:30 a.m. ET.
Interested parties may access live and archived webcasts on the company’s Investors section at www.adaptivebiotech.com.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, ADPT declined 4.95%, reflecting a moderate negative market reaction. Argus tracked a trough of -16.8% from its starting point during tracking. Our momentum scanner triggered 18 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $139M from the company's valuation, bringing the market cap to $2.68B at that time. Trading volume was above average at 1.9x the daily average, suggesting increased trading activity.
Data tracked by StockTitan Argus on the day of publication.
SEATTLE, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the following investor conferences.
- Jefferies Global Healthcare Conference in London, UK
Presentation on Wednesday, November 19, 2025, at 8:00 a.m. Greenwich Mean Time
- Piper Sandler 37th Annual Healthcare Conference in New York, NY
Fireside chat on Wednesday, December 3, 2025, at 8:30 a.m. Eastern Time
Interested parties may access live and archived webcasts of the session on the “Investors” section of the company website at: www.adaptivebiotech.com.
About Adaptive Biotechnologies
Adaptive Biotechnologies (“we” or “our”) is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. We apply our platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across our two business segments: Minimal Residual Disease (MRD) and Immune Medicine. Our commercial products and clinical pipeline enable the diagnosis, monitoring, and treatment of diseases such as cancer and autoimmune disorders. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.
ADAPTIVE INVESTORS
Karina Calzadilla, Vice President, Investor Relations and FP&A
201-396-1687
investors@adaptivebiotech.com
ADAPTIVE MEDIA
Erica Jones, Associate Corporate Communications Director
206-279-2423
media@adaptivebiotech.com
FAQ
When will Adaptive Biotechnologies (ADPT) present at the Jefferies Global Healthcare Conference?
What time is the Adaptive Biotechnologies (ADPT) fireside chat at Piper Sandler?
How can investors watch Adaptive Biotechnologies (ADPT) conference webcasts?
Will the Adaptive Biotechnologies (ADPT) presentations be archived after the conferences?
Which conferences will Adaptive Biotechnologies (ADPT) attend in November–December 2025?
Where can I find the schedule and webcast links for Adaptive Biotechnologies (ADPT) investor events?
